Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 261

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 261
---
 for differential diagnosis of AD and MCI. These protein targets are involved in biological pathways that are different,
but potentially synergistic, with DiamiR’s miRNA testing platform.

DiamiR believes that offering biomarker testing
will be critical in securing biopharma contract research work, while concurrently it has the potential to improve the clinical performance
of DiamiR’s CogniMIR test by combining miRNA with blood protein markers. Specifically, DiamiR would offer its panel
of miRNA and protein biomarkers to help identify and select MCI and early dementia participants for clinical studies. DiamiR could potentially
use its assay to monitor progression and drug response in the studies as well.

DiamiR’s understanding of the market indicates
a strong demand for such testing services from drug development companies. Clinical research collaborations with industry offer near-term
revenue opportunity for DiamiR. Biopharma Services can incorporate DiamiR’s classifiers and customized panels of miRNA and protein
biomarkers that address different scientific questions depending on disease stage (e.g. preclinical, prodromal, and/or mild/moderate),
drug target (e.g. associated with synaptic dysfunction, neuroinflammation, vascular component, etc.), target population (e.g. amyloid-positive/APOE
carriers), and intended use (e.g. screening and/or monitoring in clinical trials). These customized projects offer the potential, when
appropriate, for new joint IP to be generated and for companion diagnostic test development. Additionally, they will provide revenue to
support the expansion in operational capacity of DiamiR.

Optimize blood collection methodology.Currently, DiamiR uses plasma, separated from whole blood at the clinical site of collection, as DiamiR’s primary
source of liquid biopsy material to extract miRNA from subjects and for clinical testing. While suitable for clinical trial support and
biopharma services, this methodology can be further improved for physician offices setting to improve customer adoption and DiamiR is
currently exploring options that would allow shipment of whole blood from collection sites to its lab, where DiamiR laboratory staff would
spin down the plasma for use in CogniMIRpanel. DiamiR is testing a number of collection tubes, preservatives and extraction
methods to identify the optimal collection and shipping conditions for the clinical commercial version of its test.

Classifier and algorithm development. DiamiR
is in the process of developing a second generation software to support its LDTs in development. DiamiR